345PPhase I dose-escalation and expansion study of the PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumours
ConclusionsThe MTD of FLU was 150mg BID in advanced solid malignancies. FLU demonstrated single-agent antitumour activity in BC and OC, particularly in platinum-sensitive and BRCAMut OC.Clinical trial identificationNCT03509636.Legal entity responsible for the studyHuiping Li.FundingJiangsu Hengrui Medicine Co.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Anemia | Breast Cancer | Cancer | Cancer & Oncology | China Health | Clinical Trials | Colorectal Cancer | Hematology | Legislation | Ovarian Cancer | Ovaries | Study | Thrombocytopenia